Transgene Company Profile
TRANSGENE is a leading integrated gene therapy company, dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired and inherited diseases. The Company's proprietary technology platform consists of five vector families including three of viral origin - adenovirus, retrovirus, vaccinia virus - and two of non viral origin - cellular and synthetic vectors.
Location
11 rue de Molsheim
Strasbourg
F-67082
France
Contact
Phone: 00 33 88 27 91 00
Fax: 00 33 88 27 91 11
News Articles
Transgene and Tasly JV Starts Operations with Four Transgene Molecules
The JV established by France’s Transgene and Tasly Pharma of China announced that Transgene is contributing China rights to four biotech immunotherapeutic candidates to the JV. The JV will be...
Sanofi and Transgene enter biotech partnering
Sanofi and Transgene announced a biotech partnering agreement for the creation of a new state-of-the-art industrial platform dedicated to the production of immunotherapy products including Transgeneâ€...
India's Transgene Biotek claims early success in oral insulin for rats
The Indian company, Transgene Biotek, has reported encouraging early results for its oral delivery technology for insulin, though industry experts say it may be premature to flag up the progress made...
Sanofi, Transgene Announce Agreement For Creation Of Industrial Platform
PARIS (dpa-AFX) - Sanofi (SNY) and Transgene SA announced a collaboration agreement for the creation of an industrial platform for the production of immunotherapy products including Transgene's th...
Sanofi and Transgene collaborate on immunotherapy treatments; NAS designation of Aubagio disputed
Drug major Sanofi (Euronext: SAN) and fellow France-based biotech firm Transgene SA (NYSE-Euronext: TNG) have entered a collaboration agreement for the creation of a new state-of-the-art industrial pl...
Sanofi, Transgene form long-term collaboration for production of immunotherapy treatments
Global healthcare company Sanofi and biopharmaceutical company Transgene have signed a collaboration agreement for the creation of a new state-of-the-art industrial platform dedicated to the productio...
Transgene to Present at the Cowen & Company 33rd Annual Healthcare Conference
Regulatory News: Transgene S.A. (Paris:TNG)(Euronext Paris:FR0005175080) today announced that Philippe Archinard, Chairman & Chief Executive Officer, will be p...
Stream Value to take stake in India's Transgene as it seeks delisting
The institutional investor, Stream Value Fund, is to back the founders of Transgene Biotek as the Indian firm seeks to delist itself from the Bombay Stock Exchange. Transgene informed the stock exchan...
Drugs and Medications
None
PubMed Articles
An endogene-resembling transgene delays the onset of silencing and limits siRNA accumulation.
In plants, transgenes are generally more sensitive against RNA silencing than endogenes are. In this study, we generated a transgene that structurally mimicks an endogene. It is composed of endogenous...
In quiescent tissues, minicircle DNA vectors provide at least 10 times higher sustained levels of transgene expression compared to that achieved with a canonical plasmid containing the same expression...
A Mini-intronic Plasmid (MIP): A Novel Robust Transgene Expression Vector In Vivo and In Vitro.
The bacterial backbone (BB) sequences contained within a canonical plasmid DNA dampen exogenous transgene expression by tenfold to 1,000-fold over a period of a few weeks following transfection into q...
Multiple components in serum contribute to hepatic transgene expression by lipoplex in mice.
BACKGROUND: Interaction of cationic liposome/plasmid DNA complex (lipoplex) with serum was not a limiting factor for in vivo transfection. Following intraportal injection of lipoplex, hepatic transgen...
Endogenous microRNA (miRNA) expression can be exploited for cell type-specific transgene expression as the addition of miRNA target sequences to transgenic cDNA allows for transgene downregulation spe...
Clinical Trials
The primary objective is to evaluate the transgene expression (synthesis of FGF-1 mRNA) in injected tissue, at injection site, after Intra Muscular (IM) administration of increasing single...
This is a Phase I-II study evaluating the feasibility, safety, and efficacy of swallowed MnSOD plasmid/liposome (PL) transgene given as protection against radiation-induced esophagitis dur...
Companies
TRANSGENE is a leading integrated gene therapy company, dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired and inherited d...
Transgene (NYSE-Euronext: TNG), a member of the Institut Mérieux Group, is a biopharmaceutical company. It creates, develops and manufactures targeted immunotherapeutics for th...
Intrexon Corporation is a privately held life sciences company that employs modular DNA control systems to enhance capabilities, improve safety and lower cost in human therapeutic...
Mission StatementTransgene is a biopharmaceutical company dedicated to the discovery and development of gene-based therapeutic vaccines and immunotherapy products for the treatment of cancer and infec...
IGER (Institute for Grassland and Environmental Research)
description:Research and services in biotechnology, environment and agricultureSkills:R&D, consultancy and services in agriculture, environment and bioscienceCollaborations:contract R&D, consultancyKe...
More Information about "Transgene" on BioPortfolio
We have published hundreds of Transgene news stories on BioPortfolio along with dozens of Transgene Clinical Trials and PubMed Articles about Transgene for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Transgene Companies in our database. You can also find out about relevant Transgene Drugs and Medications on this site too.
